Kyverna Therapeutics (KYTX) Liabilities and Shareholders Equity (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $257.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 1.39% year-over-year to $257.0 million; the trailing twelve-month figure through Mar 2026 stood at $964.5 million (down 23.91% YoY), and the FY2025 full-year result was $293.8 million, down 3.55% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $257.0 million, down from $293.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $390.0 million in Q1 2024 and bottomed at $75.2 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $277.2 million (2025), against an average of $269.7 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity surged 305.14%; it then sank 44.82% in 2025.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $75.2 million in 2023, then soared by 305.14% to $304.6 million in 2024, then declined by 3.55% to $293.8 million in 2025, then decreased by 12.53% to $257.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $257.0 million (Q1 2026), $293.8 million (Q4 2025), and $187.2 million (Q3 2025), per Business Quant data.

Peer Comparison